retatrutide nash trial Retatrutide: A Promising Breakthrough for Fatty Liver Disease Phase 2 trial results demonstrate

10.1056/nejmoa1603827 46 MeurotC.MartinC.SudreL.BretonJ.BougaultC.RattenbachR.et al (2022)

Hankir MK, Seyfried F, Hintschich CA, Diep T-A, Kleberg K, Kranz M, Deuther-Conrad W, Tellez LA, Rullmann M, Patt M, Teichert J, Hesse S, Sabri O, Brust P, Hansen HS, de Araujo IE, Krgel U, Fenske WK

Unlike fad diets or extreme exercise plans, LIV Lean focuses on metabolic optimization, appetite control, and fat reduction while preserving muscle tone

doi:10.7759/cureus.85531 40

She cites her own non-peer-reviewed reports and transgender-advocacy groups clinical guidelines but fails to mention four extant systematic reviews of evidencethe gold standard in evidence evaluationall finding that the evidence for endocrine treatments was of low or very low quality